Bibliography
- Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004;431:343-9
- Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 2005;309:1519-24
- Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003;4:457-67
- Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007;8:23-36
- Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet 2009;10:94-108
- Cerutti H, Casas-Mollano JA. On the origin and functions of RNA-mediated silencing: from protists to man. Curr Genet 2006;50:81-99
- RNAi Glossary. 2009. Available from: http://www.rnaiweb.com/RNAi/RNAi_Glossary [last accessed 10 July 2009]
- Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8
- Patzel V, Rutz S, Dietrich I, et al. Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency. Nat Biotechnol 2005;23:1440-4
- Huesken D, Lange J, Mickanin C, et al. Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol 2005;23:995-1001
- Reynolds A, Leake D, Boese Q, et al. Rational siRNA design for RNA interference. Nat Biotechnol 2004;22:326-30
- Kassner PD. Discovery of novel targets with high throughput RNA interference screening. Comb Chem High Throughput Screen 2008;11:175-84
- Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007;6:556-68
- Constans A. RNAi: five tips to better silencing. Scientist 2006;20(1):71
- Eguchi A, Meade BR, Chang YC, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 2009;27:567-71
- Root DE, Hacohen N, Hahn WC, et al. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods 2006;3:715-19
- Table 2: Gene list with corresponding clone ID# and percent remaining gene expression. The cancer genome anatomy project. Available from: http://cgap.nci.nih.gov/RNAi/Table_2 [Last accessed 21 July 2009]
- Krausz E. High-content siRNA screening. Mol Biosyst 2007;3:232-40
- Bassik MC, Lebbink RJ, Churchman LS, et al. Rapid creation and quantitative monitoring of high coverage shRNA libraries. Nat Methods 2009, published online17 May 2009, doi:10.1038/nmeth.1330
- Silva JM, Marran K, Parker JS, et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 2008;319:617-20
- Brummelkamp TR, Fabius AW, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006;2:202-6
- Berns K, Hijmans EM, Mullenders J, et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004;428:431-7
- Ngo VN, Davis RE, Lamy L, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006;441:106-10
- Hattori H, Zhang X, Jia Y, et al. RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells. Blood 2007;110:640-50
- Kolfschoten IG, van Leeuwen B, Berns K, et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 2005;121:849-58
- Westbrook TF, Martin ES, Schlabach MR, et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 2005;121:837-48
- Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9
- Agrawal S, Kandimalla ER. Antisense and siRNA as agonists of Toll-like receptors. Nat Biotech 2004;22:1533-7
- Birmingham A, Anderson EM, Reynolds A, et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006;3:199-204
- Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 2006;12:1179-87
- Lin X, Ruan X, Anderson MG, et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res 2005;33:4527-35
- Echeverri CJ, Perrimon N. High-throughput RNAi screening in cultured cells: a user's guide. Nat Rev Genet 2006;7:373-84
- Sachse C, Krausz E, Krönke A, et al. High-throughput RNA interference strategies for target discovery and validation by using synthetic short interfering RNAs: functional genomics investigations of biological pathways. Methods Enzymol 2005;392:242-77
- Zhang XD, Ferrer M, Espeseth AS, et al. The use of strictly standardized mean difference for hit selection in primary RNA interference high-throughput screening experiments. J Biomol Screen 2007;12:497-509
- Boutros M, Bras LP, Huber W. Analysis of cell-based RNAi screens. Genome Biol 2006;7:R66. Published online 25 July 2006, doi:10.1186/gb-2006-7-7-r66
- Zhang XD. A pair of new statistical parameters for quality control in RNA interference high-throughput screening assays. Genomics 2007;89:552-61
- Echeverri CJ, Beachy PA, Baum B, et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 2006;3:777-9
- Available from: http:// www.broad.mit.edu/gsea/
- Brown CK, Rini BI, Connell PP, Posner MC. Holland-Frei manual of cancer medicine Hamilton, Ontario: BC Decker, 2005
- Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006;24:37-77
- Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nat Rev Drug Discov 2007;6:115-20
- Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68:3077-80
- Luo B, Cheung HW, Subramanian A, et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 2008;105:20380-5
- Schlabach MR, Luo J, Solimini NL, et al. Cancer proliferation gene discovery through functional genomics. Science 2008;319:620-4
- Silva JM, Marran K, Parker JS, et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 2008;319:617-20
- Firestein R, Bass AJ, Kim SY, et al. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity. Nature 2008;455:547-51
- Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676-9
- Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-74
- DasGupta R, Kaykas A, Moon RT, Perrimon N. Functional genomic analysis of the Wnt-wingless signaling pathway. Science 2005;308:826-33
- Major MB, Roberts BS, Berndt JD, et al. New regulators of Wnt/β-catenin signaling revealed by integrative molecular screening. Sci Signal 2008;1(ra12), published online 11 November 2008, doi: 10.1126/scisignal.2000037
- Tang W, Dodge M, Gundapaneni D, et al. A genome-wide RNAi screen for Wnt/β-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. Proc Natl Acad Sci USA 2008;105:9697-702
- Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell 2007;128:225-31
- Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305-19
- Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005;23:222-6
- Chu CY, Rana TM. Potent RNAi by short RNA triggers. RNA 2008;14:1714-19
- Grimm D. Asymmetry in siRNA design. Gene Ther 2009;16:827-9
- Ziauddin J, Sabatini DM. Microarrays of cells expressing defined cDNAs. Nature 2001;411:107-10
- Wheeler DB, Bailey SN, Guertin DA, et al. RNAi living-cell microarrays for loss-of-function screens in Drosophila melanogaster cells. Nat Methods 2004;1:127-32
- Erfle H, Neumann B, Liebel U, et al. Reverse transfection on cell arrays for high content screening microscopy. Nat Protoc 2007;2:392-9
- Neumann B, Held M, Liebel U, et al. High-throughput RNAi screening by time-lapse imaging of live human cells. Nat Methods 2006;3:385-90
- Bailey SN, Ali SM, Carpenter AE, et al. Microarrays of lentiviruses for gene function screens in immortalized and primary cells. Nat. Methods 2006;3:117-22
- Paran Y, Lavelin I, Naffar-Abu-Amara S, et al. Development and application of automatic high-resolution light microscopy for cell-based screens. Methods Enzymol 2006;414:228-47
- Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001;29:365-71
- Minimum Information About an RNAi Experiment (MIARE) HomePage. Available from: http://miare.sourceforge.net/ HomePage [Last accesssed 21 July 2009]
- Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
- Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554
- Ma Y, Creanga A, Lum L, Beachy PA. Prevalence of off-target effects in Drosophila RNA interference screens. Nature 2006;443:359-63
- Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature 2008;454:226-31
- Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006;7:773-82
- Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 2006;6:593-602
- Kaneto H, et al. PDX-1 functions as a master factor in the pancreas. Front Biosci 2008;13:6406-20
- Kuo CJ, Matsuoka TA, Miyatsuka T, et al. A transcriptional hierarchy involved in mammalian cell-type specification. Nature 1992;355:457-61
- Pownall ME, Gustafsson MK, Emerson CP Jr. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. Annu Rev Cell Dev Biol 2002;18:747-83
- Reddy A, Kaelin WG Jr. Using cancer genetics to guide the selection of anticancer drug targets. Curr Opin Pharmacol 2002;2:366-73
- Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008;8:363-9
- Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-12
- Wang Y, Quon KC, Knee DA, et al. RAS, MYC, and sensitivity to tumor necrosis factor-α-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2005;65:1615-16
- Kotliarova S, Pastorino S, Kovell LC, et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-κB, and glucose regulation. Cancer Res 2008;68:6643-51
- Rottmann S, Wang Y, Nasoff M, et al. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3β/FBW7 loss of function. Proc Natl Acad Sci USA 2005;102:15195-200
- Tong AH, Lesage G, Bader GD, et al. Global mapping of the yeast genetic interaction network. Science 2004;303:808-13
- Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129-38
- Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008;134:577-86
- Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008;16:1481-9
- Peer D, Park EJ, Morishita Y, et al. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008;319:627-30
- Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009;6:659-68
- Ikeda Y, Taira K. Ligand-targeted delivery of therapeutic siRNA. Pharm Res 2006;23:1631-40
- Jones D. Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov 2009;8:525-6